Cargando…

The myocardial phenotype of Fabry disease pre-hypertrophy and pre-detectable storage

AIMS: Cardiac involvement in Fabry disease (FD) occurs prior to left ventricular hypertrophy (LVH) and is characterized by low myocardial native T1 with sphingolipid storage reflected by cardiovascular magnetic resonance (CMR) and electrocardiogram (ECG) changes. We hypothesize that a pre-storage my...

Descripción completa

Detalles Bibliográficos
Autores principales:	Augusto, João B, Johner, Nicolas, Shah, Dipen, Nordin, Sabrina, Knott, Kristopher D, Rosmini, Stefania, Lau, Clement, Alfarih, Mashael, Hughes, Rebecca, Seraphim, Andreas, Vijapurapu, Ravi, Bhuva, Anish, Lin, Linda, Ojrzyńska, Natalia, Geberhiwot, Tarekegn, Captur, Gabriella, Ramaswami, Uma, Steeds, Richard P, Kozor, Rebecca, Hughes, Derralynn, Moon, James C, Namdar, Mehdi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2020
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8219366/ https://www.ncbi.nlm.nih.gov/pubmed/32514567 http://dx.doi.org/10.1093/ehjci/jeaa101

Ejemplares similares

Myocardial Storage, Inflammation, and Cardiac Phenotype in Fabry Disease After One Year of Enzyme Replacement Therapy
por: Nordin, Sabrina, et al.
Publicado: (2019)

Cardiac Phenotype of Prehypertrophic Fabry Disease
por: Nordin, Sabrina, et al.
Publicado: (2018)

Study of indications for cardiac device implantation and utilisation in Fabry cardiomyopathy
por: Vijapurapu, Ravi, et al.
Publicado: (2019)

A randomised controlled trial evaluating arrhythmia burden, risk of sudden cardiac death and stroke in patients with Fabry disease: the role of implantable loop recorders (RaILRoAD) compared with current standard practice
por: Vijapurapu, Ravi, et al.
Publicado: (2019)

Cardiac device implantation and device usage in Fabry and hypertrophic cardiomyopathy
por: Vijapurapu, Ravi, et al.
Publicado: (2022)

Systematic review of the incidence and clinical risk predictors of atrial fibrillation and permanent pacemaker implantation for bradycardia in Fabry disease
por: Vijapurapu, Ravi, et al.
Publicado: (2023)

A Novel Rapid MALDI-TOF-MS-Based Method for Measuring Urinary Globotriaosylceramide in Fabry Patients
por: Alharbi, Fahad J., et al.
Publicado: (2016)

Increased cardiac involvement in Fabry disease using blood-corrected native T1 mapping
por: Nickander, Jannike, et al.
Publicado: (2023)

Fabry disease and incidence of cancer
por: Bird, Sarah, et al.
Publicado: (2017)

Atherosclerosis in Fabry Disease—A Contemporary Review
por: Roy, Ashwin, et al.
Publicado: (2021)

Saturation-pulse prepared heart-rate independent inversion-recovery (SAPPHIRE) biventricular T1 mapping: inter-field strength, head-to-head comparison of diastolic, systolic and dark-blood measurements
por: Alfarih, Mashael, et al.
Publicado: (2022)

Long-term effectiveness of agalsidase alfa enzyme replacement in Fabry disease: A Fabry Outcome Survey analysis
por: Beck, Michael, et al.
Publicado: (2015)

Prospective cardiovascular magnetic resonance imaging in adults with Alström syndrome: silent progression of diffuse interstitial fibrosis
por: Baig, Shanat, et al.
Publicado: (2020)

Safety and efficacy of pegunigalsidase alfa in patients with Fabry disease who were previously treated with agalsidase alfa: results from BRIDGE, a phase 3 open-label study
por: Linhart, Aleš, et al.
Publicado: (2023)

An unusual cause of polymorphic ventricular tachycardia: Acquired long QT syndrome from atypical variant of stress-induced cardiomyopathy
por: Alfarih, Mashael, et al.
Publicado: (2020)

Toward a consensus in the laboratory diagnostics of Fabry disease - recommendations of a European expert group
por: Gal, Andreas, et al.
Publicado: (2011)

Individualised Approaches for Catheter Ablation of AF: Patient Selection and Procedural Endpoints
por: Johner, Nicolas, et al.
Publicado: (2019)

Safety, Efficacy and Prognostic Benefit of Atrial Fibrillation Ablation in Heart Failure with Preserved Ejection Fraction
por: Johner, Nicolas, et al.
Publicado: (2022)

Recommendations for initiation and cessation of enzyme replacement therapy in patients with Fabry disease: the European Fabry Working Group consensus document
por: Biegstraaten, Marieke, et al.
Publicado: (2015)

Management of pain in Fabry disease in the UK clinical setting: consensus findings from an expert Delphi panel
por: Stepien, Karolina M., et al.
Publicado: (2023)

Clinical prodromes of neurodegeneration in Anderson-Fabry disease
por: Löhle, Matthias, et al.
Publicado: (2015)

The significance of pulmonary veins isolation radiofrequency time and the evolution of left atrium volume on a twelve-year observational follow-up of paroxysmal atrial fibrillation patients
por: Buffle, Eric, et al.
Publicado: (2022)

Changes in LA volume and diameter correlate with mechanisms of recurrence after paroxysmal AF ablation
por: Buffle, Eric, et al.
Publicado: (2022)

Progressive cardiac involvement in a compound heterozygote Fabry patient: a case report
por: McConnell, Eliza Jeanette, et al.
Publicado: (2018)

Familial cardiomyopathy caused by a novel heterozygous mutation in the gene LMNA (c.1434dupG): a cardiac MRI-augmented segregation study
por: ALFARIH, MASHAEL, et al.
Publicado: (2019)

Cardiomyopathy and kidney function in agalsidase beta‐treated female Fabry patients: a pre‐treatment vs. post‐treatment analysis
por: Wanner, Christoph, et al.
Publicado: (2020)

Cardio- Renal Outcomes With Long- Term Agalsidase Alfa Enzyme Replacement Therapy: A 10- Year Fabry Outcome Survey (FOS) Analysis
por: Ramaswami, Uma, et al.
Publicado: (2019)

Inline perfusion mapping provides insights into the disease mechanism in hypertrophic cardiomyopathy
por: Camaioni, Claudia, et al.
Publicado: (2020)

Estimation of Health State Utility Values in Fabry Disease Using Vignette Development and Valuation
por: Hughes, Derralynn, et al.
Publicado: (2023)

Measures to mitigate disruption due to the COVID-19 pandemic of the MODIFY phase 3 pivotal trial in patients with Fabry disease
por: Frey, Aline, et al.
Publicado: (2021)

Migalastat HCl Reduces Globotriaosylsphingosine (Lyso-Gb(3)) in Fabry Transgenic Mice and in the Plasma of Fabry Patients
por: Young-Gqamana, Brandy, et al.
Publicado: (2013)

Diagnosis of Acute Cholecystitis Using T1 and T2 Mapping by Cardiac MRI
por: Sen, Gautam, et al.
Publicado: (2023)

Apical Hypertrophic Cardiomyopathy: The Variant Less Known
por: Hughes, Rebecca K., et al.
Publicado: (2020)

Electrocardiographic Changes and Arrhythmia in Fabry Disease
por: Namdar, Mehdi
Publicado: (2016)

Prompt Agalsidase Alfa Therapy Initiation is Associated with Improved Renal and Cardiovascular Outcomes in a Fabry Outcome Survey Analysis
por: Hughes, Derralynn, et al.
Publicado: (2021)

Myocardial characterization in pre-dialysis chronic kidney disease: a study of prevalence, patterns and outcomes
por: Price, Anna M., et al.
Publicado: (2019)

Myocardial Perfusion Defects in Hypertrophic Cardiomyopathy Mutation Carriers
por: Hughes, Rebecca K., et al.
Publicado: (2021)

ECG, LVH and T1 changes in Fabry disease - implications for screening and understanding of the disease model
por: Kozor, Rebecca, et al.
Publicado: (2016)

Biomarkers of Myocardial Fibrosis: Revealing the Natural History of Fibrogenesis in Fabry Disease Cardiomyopathy
por: Aguiar, Patrício, et al.
Publicado: (2018)

Do clinical guidelines facilitate or impede drivers of treatment in Fabry disease?
por: Hughes, Derralynn A., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_ale3m5cnja7vq20qeqsikhurko